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PRELIMINARY AND SHORT REPORTS
INTENSIVE PANTHENOL THERAPY OF LUPUS ERYTIIEMATOSUS*
LEON GOLDMAN, M.D.
Since the previous report (1) on the treatment of subacute and chronic discoid lupus
erythematosus with calcium pantothenate, additional patients with this disease and re-
lated disorders have been treated. As our chief therapeutic agent, calcium pantothenate
TABLE 1
Intensive panthenol therapy of acute disseminated lupus erythematosus
NO. DOSAGE PANTEENOL DURATIONDOSAGE OTHER THERAPIES RESULT
gNT.
1 1.5 3 weeks Penicillin Died
1,000,000 per
day
2 1.8 2 weeks ACTH No response. Panthenol not
used after ACTH remis-
sion. Later child died with
pericarditis.
3 2.3 6 weeks None Improved remarkably. Later
relapsed when not under
therapy.
4 2 4 weeks ACTH, Corti- No effect of calcium pan-
(calcium pan- sone tothenate later improve-
tothenate) ment from ACTH and Cor-
tisone.
5 2 5 days ACTH Some initial fading skin le-
sions before ACTH started.
Patient died renal failure
while under ACTH.
6 2.3 3 weeks Transfusion, Died
Penicillin
7 4 2 months Cortisone Subacute phase responded
to Panthenol. Later re-
lapsed when Panthenol dis-
continued. Cortisone used.
Good temporary response
to Cortisone.
8 3 2 months None Eruption cleared, General
condition improved but low
grade fever and anemia
persisted. Patient is an el-
derly woman 75 years old,
still living.
9 4 1 month ACTH, Cortisone Panthenol had no effect
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has been replaced largely by pantenol, the alcohol of pantothenic acid. It is hoped to deter-
mine the effectiveness of panthenol' as an adjuvant to ACTH, Cortisone' and to achieve a
comparison on the basis of therapeutic efficacy, with such other agents as sodium para-
aminobenzoate (NaPABA), the tocopherols, bismuth and gold. The recent work of Morgan
(2) suggests some relationship between ACTH, Cortisone and the relief of prolonged panto-
thenic acid deficiency, this worker having found the adrenal gland to be affected in both
riboflavin and pantothenic acid deficiencies. For use in this study an experimental supply
of panthenol was made available to us in the form of capsules containing 0.5 grams each.
TABLE 2
Intensive panthenol therapy of subacute disseminated lupus erythematosus
NO. PANTKENOL DURATION DOSAGE RESULT
1 0.5 4 weeks 0 Improved
2 2 3 weeks 0 Improved. Maintained regime 0.5 gm.—
2 months.
3 1.5 6 weeks 0 Improved
4 2.3 2 months 0 Improvement began 3 weeks same dosage
continued.
5 3.5 1 month 0 Improved
6 4 2.5 months 0 Improved
7 4 3 months 0 Improved
8 3.5 2 months 0 Improved
9 6 2.5 months 0 Flared with development of arthritis
and acute dissemination.
10 4.5 1 month 0 Improved
TABLE 3
Intensive panthenol therapy of discoid lupus erythematosus
DURATION
Less than five years
More than five years
NO.
18
9
PRRVIOUS
12
9
IMPROVED
12
5
CURED
3
1
(Disseminate
variety)
RERRAC-
TORY
3
3
AGGRAVATED
0
1
(New lesions.
Older cleared.)
There is apparently no toxicity of panthenol even at dosage levels of 8-10 grams daily, our
maximum daily dose. Patients have been maintained on 1 and 2 grams daily for as long
as six months. Sevringhaus (3) has indicated, "We have not been able to find a lethal dose
for 50% of the animals because panthenol is so well tolerated that you can give several
grams per kilo. Therefore, we do not know any toxic upper limit to dosage that can be
predicted." From study of nine cases of acute disseminated lupus erythematosus, only
two had improvement. However, because of its freedom from toxicity the drug may be
used in conjunction with ACTH or Cortisone and may be part of a so-called maintenance
routine after remission has occurred. This is utider study at the present time. Bauer (4) has
'Panthenol furnished by Dr. Elmer L. Sevringhaus of Hoffman-La Roche, Inc.
2 Cortisone (Cortone Acetate) furnished by Dr. J. M. Carlisle of Merck and Company
Inc.
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had no effect in three cases when a maintenance dose was administered. The best result8
were in cases of subacute lupus erythematosus in which 3 to 4 grams of panthenol were given
daily for an initial trial period of 3 weeks. Welsh (5) has had good response in 7 cases. In
discoid lupus erythematosus a 2 months trial period is advised, doses in the magnitude of
8 to 10 grains may be employed. When ACTH and Cortisone are used in subacute and
chronic discord phases, Panthenol may be given as maintenance regime to prevent a relapse.
In addition, topical forms of covering material was recommended for superficial types.
When the border was infiltrated or hypertrophic, phenol, or carbon dioxide cauterization
was done.
CONCLUSIONS
Panthenol, the alcohol of pantothenic acid, is suggested as an adjuvant to ACTU and
cortisone in acute disseminated lupus erythematosus and as a sole remedial systemic agent
at present in subacute lupus erythematosus and chronic discoid lupus erythematosus.
When ACTIJ and Cortisone are used in the therapy of these forms of lupus erythemato-
sus, panthenol may be used after remission has occured to prevent a relapse.
REFERENCES
1. Goui&a, L.: Treatment of Subacute and Chronic Discoid Lupus Erythematosus with
Intensive Calcium Pentothenate Therapy. J. Invest. Dermat. 11: 95, August, 1948.
2. Moau&N, A. F.: Garvan Medal Address, 116th Meeting, American Chemical Society,
Atlantic City, September, 1949.
3. SaviuNoa&us, E. L.: Personal communication.
4. Bsuaa, W&LvEB: Personal communication.
5. Waran, ABBTON: Personal Communication.
